echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lukang Pharmaceutical's Ticagrelor Tablets obtained the "Drug Registration Certificate"

    Lukang Pharmaceutical's Ticagrelor Tablets obtained the "Drug Registration Certificate"

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 11, Lukang Pharmaceutical announced that it had received the "Drug Registration Certificate" (certificate number: 2021S01335) for Ticagrelor Tablets issued by the State Food and Drug Administration


    Ticagrelor Tablets, developed by AstraZeneca, is the first reversibly binding, direct-acting, orally administered platelet adenosine diphosphate P2Y12 receptor antagonist, which can effectively reduce the activity of platelets in the blood and reduce the Risk of thrombosis


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.